February 8, 2017 | Written by: Brian Langarica Nielsen
Categorized: Analytics | Watson
Share this post:
It is my pleasure to announce that IBM Watson Health is entering an exciting collaboration with global pharmaceutical company Lundbeck.
Lundbeck is tapping into IBM Watson Health’s cognitive and knowledge-based health data analytics platform to speed the discovery and development of treatments for psychiatric and neurological disorders, including schizophrenia and Parkinson’s disease. The collaboration aims to combine Lundbeck’s knowhow in the field of neurological and psychiatric disease therapy with the IBM Watson platform to derive information from clinical data through the Watson Health Cloud. The collaboration means that Lundbeck will get access to anonymous health data from millions of patients in the Watson Health Cloud.
The collaboration will also enable Lundbeck to use IBM Watson technologies across its own clinical data and other data and harness the IBM Watson platform to enable a knowledge-driven approach that it maintains will support the identification of new drug targets and drug indications. The work will initially focus on deriving new understanding and potential treatments in the areas of schizophrenia and Parkinson’s disease.
Click here to learn more about the collaboration.
Please don’t hesitate to get in contact with me at firstname.lastname@example.org if you have any questions.